ACC CardiaCast: Mechanisms of Action for the Newly Approved Cardiac Myosin Inhibitor Recently Approved for HCM

Jun 16, 2022   |  Ahmad Masri, MD, FACC; Matthew W. Martinez, MD, FACC

Podcast

Font Size
A
A
A

In this episode, Drs. Matt Martinez and Ahmad Masri discuss the recent approval by the FDA of the cardiac myosin inhibitor Mavacamten for the treatment of hypertrophic cardiomyopathy, and mechanisms of action.




Clinical Topics: Heart Failure and Cardiomyopathies

Keywords: Cardiomyopathy, Hypertrophic, CardiaCast


< Back to Listings